湖南南新制药股份有限公司2025年年度业绩预亏公告

Group 1 - The company expects a significant decline in revenue for the year 2025, projecting an operating income between 120 million to 150 million yuan, a decrease of 113.28 million to 143.28 million yuan compared to the previous year, representing a year-on-year decline of 43.03% to 54.42% [3] - The company anticipates a net loss attributable to shareholders of the parent company ranging from -160 million to -120 million yuan, which is a reduction in loss of 196.90 million to 236.90 million yuan compared to the previous year, indicating a year-on-year decrease in loss of 55.17% to 66.38% [3] - The projected net loss attributable to shareholders after excluding non-recurring gains and losses is expected to be between -165 million to -125 million yuan, with a reduction in loss of 193.53 million to 233.53 million yuan compared to the previous year, reflecting a year-on-year decrease in loss of 53.98% to 65.14% [4] Group 2 - The company reported a total profit loss of -388.64 million yuan for the year 2024, with a net loss attributable to shareholders of the parent company at -356.90 million yuan [6] - The earnings per share for the year 2024 were reported at -1.3007 yuan [7] Group 3 - The decline in performance is attributed to intensified market competition due to domestic pharmaceutical industry procurement policies and the introduction of similar competing products, along with a decrease in flu cases in the first three quarters of 2025, leading to reduced operating income and gross margin [8] - The company has maintained a high level of R&D investment to sustain its core competitiveness while implementing cost control measures, resulting in a significant decrease in sales and management expenses compared to the previous year [8] - Future strategies include adjusting marketing strategies, accelerating R&D progress, launching new products, optimizing product sales structure, and enhancing cost management to achieve sustainable and high-quality development [8]